$PLRX
PLIANT THERAPEUTICS, INC. Stock $plrx

$plrx Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000174647323000031 Filed on May 09, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$248.0K	$1.332M	$1.249M
YoY Change	-95.03%	6.65%	-42.55%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$14.57M	$14.15M	$8.579M
YoY Change	75.68%	64.98%	30.58%
% of Gross Profit
Research & Development	$33.00M	$29.27M	$20.88M
YoY Change	25.32%	40.19%	12.71%
% of Gross Profit
Depreciation & Amortization	$477.0K	$500.0K	$500.0K
YoY Change	-4.6%	0.0%	25.0%
% of Gross Profit
Operating Expenses	$47.58M	$43.43M	$29.46M
YoY Change	37.38%	47.41%	17.4%
Operating Profit	-$47.33M	-$42.10M	-$28.21M
YoY Change	59.67%	49.21%	23.09%
Interest Expense	$319.0K	$311.0K	$111.0K
YoY Change	232.29%	180.18%	85.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$41.19M	-$37.55M	-$28.10M
YoY Change	39.42%	33.62%	22.92%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$41.19M	-$37.55M	-$28.10M
YoY Change	39.42%	33.62%	22.94%
Net Earnings / Revenue	-16609.68%	-2818.92%	-2249.8%
Basic Earnings Per Share	-$0.70	-$0.67	-$0.78
Diluted Earnings Per Share	-$0.70	-$0.67	-$0.78
COMMON SHARES
Basic Shares Outstanding	59.16M shares	58.94M shares	36.12M shares
Diluted Shares Outstanding	59.17M shares	56.06M shares	36.12M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$555.2M	$577.3M	$178.3M
YoY Change	239.35%	223.82%	-32.5%
Cash & Equivalents	$54.95M	$102.5M	$32.55M
Short-Term Investments	$500.2M	$474.8M	$145.7M
Other Short-Term Assets	$6.520M	$6.156M	$5.751M
YoY Change	34.24%	7.04%	36.93%
Inventory
Prepaid Expenses
Receivables	$1.580M	$3.297M	$1.249M
Other Receivables	$2.442M	$1.460M	$83.00K
Total Short-Term Assets	$565.7M	$588.2M	$185.4M
YoY Change	226.0%	217.34%	-31.48%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.518M	$4.197M	$4.738M
YoY Change	87.87%	-11.42%	11.06%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$672.0K	$644.0K	$835.0K
YoY Change	-26.4%	-22.87%	85.14%
Total Long-Term Assets	$9.190M	$9.654M	$11.66M
YoY Change	-17.15%	-17.2%	147.17%
TOTAL ASSETS
Total Short-Term Assets	$565.7M	$588.2M	$185.4M
Total Long-Term Assets	$9.190M	$9.654M	$11.66M
Total Assets	$574.9M	$597.9M	$197.0M
YoY Change	211.39%	203.46%	-28.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.310M	$1.419M	$4.684M
YoY Change	-25.87%	-69.71%	62.3%
Accrued Expenses	$27.21M	$21.73M	$11.63M
YoY Change	56.42%	86.94%	57.88%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$1.999M
YoY Change
Total Short-Term Liabilities	$29.52M	$23.15M	$18.31M
YoY Change	30.89%	26.46%	78.62%
LONG-TERM LIABILITIES
Long-Term Debt	$9.988M	$9.958M	$4.920M
YoY Change	-30.05%	102.4%
Other Long-Term Liabilities	$2.318M	$2.850M	$4.920M
YoY Change	-47.4%	-42.07%	489.22%
Total Long-Term Liabilities	$12.31M	$12.81M	$4.920M
YoY Change	-13.81%	160.33%	489.22%
TOTAL LIABILITIES
Total Short-Term Liabilities	$29.52M	$23.15M	$18.31M
Total Long-Term Liabilities	$12.31M	$12.81M	$4.920M
Total Liabilities	$41.83M	$35.96M	$23.23M
YoY Change	13.56%	54.81%	109.55%
SHAREHOLDERS EQUITY
Retained Earnings	-$417.2M	-$376.0M	-$243.2M
YoY Change	52.95%	54.59%	72.86%
Common Stock	$952.5M	$939.2M	$417.9M
YoY Change	125.82%	124.73%	3.23%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$533.1M	$561.9M	$173.8M
YoY Change
Total Liabilities & Shareholders Equity	$574.9M	$597.9M	$197.0M
YoY Change	211.39%	203.46%	-28.42%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$41.19M	-$37.55M	-$28.10M
YoY Change	39.42%	33.62%	22.94%
Depreciation, Depletion And Amortization	$477.0K	$500.0K	$500.0K
YoY Change	-4.6%	0.0%	25.0%
Cash From Operating Activities	-$24.76M	-$30.28M	-$20.50M
YoY Change	1.49%	47.7%	50.0%
INVESTING ACTIVITIES
Capital Expenditures	$603.0K	$163.0K	$644.0K
YoY Change	-337.4%	-74.69%	166.12%
Acquisitions
YoY Change
Other Investing Activities	-$22.38M	-$174.0M	$2.175M
YoY Change	-431.53%	-8102.07%	-82.56%
Cash From Investing Activities	-$22.98M	-$174.2M	$1.531M
YoY Change	-453.78%	-11478.71%	-87.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	161.0K	$273.3M	-$153.0K
YoY Change	-98.46%	-178744.44%	-111.17%
NET CHANGE
Cash From Operating Activities	-24.76M	-$30.28M	-$20.50M
Cash From Investing Activities	-22.98M	-$174.2M	$1.531M
Cash From Financing Activities	161.0K	$273.3M	-$153.0K
Net Change In Cash	-47.58M	$68.84M	-$19.12M
YoY Change	536.47%	-460.05%	30249.21%
FREE CASH FLOW
Cash From Operating Activities	-$24.76M	-$30.28M	-$20.50M
Capital Expenditures	$603.0K	$163.0K	$644.0K
Free Cash Flow	-$25.36M	-$30.44M	-$21.14M
YoY Change	5.05%	43.97%	52.02%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001746473
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-39303
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	PLIANT THERAPEUTICS, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-4272481
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	260 Littlefield Avenue
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	South San Francisco,
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94080
CY2023Q1	dei	City Area Code CityAreaCode	650
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	481-6770
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2023Q1	dei	Trading Symbol TradingSymbol	PLRX
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	59156444	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	102527000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	33685000	usd
CY2023Q1	us-gaap	Short Term Investments ShortTermInvestments	474787000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	297502000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3297000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1983000	usd
CY2023Q1	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	83000	usd
CY2022Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	83000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7533000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7058000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	588227000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	340311000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4197000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4486000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4813000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5422000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	644000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	394000	usd
CY2023Q1	us-gaap	Assets Assets	597881000	usd
CY2022Q4	us-gaap	Assets Assets	350613000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1419000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1580000	usd
CY2023Q1	plrx	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	14621000	usd
CY2022Q4	plrx	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	11218000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	4733000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	8658000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2380000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2457000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	23153000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	23913000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2850000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3429000	usd
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	9958000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	9929000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	35961000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	37271000	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	58978902	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	58978902	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48941254	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48941254	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	5000	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	939205000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	653707000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-375960000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-338412000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1331000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1958000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	561920000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	313342000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	597881000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	350613000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1332000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1249000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	29273000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20881000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14154000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8579000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	43427000	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	29460000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-42095000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-28211000	usd
CY2023Q1	plrx	Interest And Other Income Expense Net InterestAndOtherIncomeExpenseNet	4858000	usd
CY2022Q1	plrx	Interest And Other Income Expense Net InterestAndOtherIncomeExpenseNet	111000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	311000	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	0	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-37548000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-28100000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-37548000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-37548000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-28100000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-28100000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.67
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.78
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.67
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.78
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	56057603	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36116440	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	56057603	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36116440	shares
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-37548000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-28100000	usd
CY2023Q1	plrx	Oci Short Term Investments And Cash Equivalents Unrealized Holding Gain Loss Before Adjustment After Tax OCIShortTermInvestmentsAndCashEquivalentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax	627000	usd
CY2022Q1	plrx	Oci Short Term Investments And Cash Equivalents Unrealized Holding Gain Loss Before Adjustment After Tax OCIShortTermInvestmentsAndCashEquivalentsUnrealizedHoldingGainLossBeforeAdjustmentAfterTax	-749000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	627000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-749000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-36921000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-28849000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	313342000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	269915000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3661000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11923000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	627000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-37548000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	561920000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	199059000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	1000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	51000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3531000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-749000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-28100000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	173793000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-37548000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-28100000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	452000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	455000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	11923000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3531000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	609000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	244000	usd
CY2023Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	2584000	usd
CY2022Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-272000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1314000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-749000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	476000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1013000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	usd
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-207000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-144000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1770000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-538000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-364000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-656000	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-275000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-30276000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20498000	usd
CY2023Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	276620000	usd
CY2022Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	39228000	usd
CY2023Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	102575000	usd
CY2022Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Shortterm Investments ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments	41403000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	163000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	644000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-174208000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1531000	usd
CY2023Q1	plrx	Proceeds From Issuances Of Common Stock Under Benefit Plans ProceedsFromIssuancesOfCommonStockUnderBenefitPlans	3661000	usd
CY2022Q1	plrx	Proceeds From Issuances Of Common Stock Under Benefit Plans ProceedsFromIssuancesOfCommonStockUnderBenefitPlans	51000	usd
CY2023Q1	plrx	Payments Of Deferred Offering Costs PaymentsOfDeferredOfferingCosts	586000	usd
CY2022Q1	plrx	Payments Of Deferred Offering Costs PaymentsOfDeferredOfferingCosts	204000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	270251000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	273326000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-153000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	68842000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-19120000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	33685000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	51665000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	102527000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	32545000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	282000	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	0	usd
CY2023Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	636000	usd
CY2022Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-749000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:18pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and expenses as well as the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, stock-based compensation expense and accruals for research and development costs. The Company assesses estimates on an ongoing basis, however, actual results could materially differ from those estimates.</span></div>
CY2023Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	559162000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	58000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	1391000	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	557831000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	327771000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	45000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	2003000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	325813000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11490000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11327000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7293000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6841000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4197000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4486000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	500000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	500000	usd
CY2023Q1	plrx	Prepaid Research And Development Current PrepaidResearchAndDevelopmentCurrent	3305000	usd
CY2022Q4	plrx	Prepaid Research And Development Current PrepaidResearchAndDevelopmentCurrent	3421000	usd
CY2023Q1	us-gaap	Prepaid Insurance PrepaidInsurance	935000	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1427000	usd
CY2023Q1	plrx	Prepaid Licenses Current PrepaidLicensesCurrent	1498000	usd
CY2022Q4	plrx	Prepaid Licenses Current PrepaidLicensesCurrent	959000	usd
CY2023Q1	us-gaap	Interest Receivable Current InterestReceivableCurrent	1377000	usd
CY2022Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	1078000	usd
CY2023Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	418000	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	173000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7533000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7058000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3447000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7200000	usd
CY2023Q1	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	1286000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	1458000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	4733000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	8658000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	0	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	0	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	5455000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	4545000	usd
CY2023Q1	plrx	Long Term Debt Maturity After Year Four LongTermDebtMaturityAfterYearFour	0	usd
CY2023Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	10000000	usd
CY2023Q1	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	127000	usd
CY2023Q1	plrx	Long Term Debt Accretion Of Final Payment LongTermDebtAccretionOfFinalPayment	85000	usd
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	9958000	usd
CY2023Q1	plrx	Number Of Classes Of Stock Authorized NumberOfClassesOfStockAuthorized	2	class
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Voting Rights CommonStockVotingRights	The holders of shares of common stock are entitled to one vote for each share of common stock held at any meeting of stockholders and at the time of any written action in lieu of a meeting.
CY2023Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0
CY2023Q1	us-gaap	Common Stock Dividends Per Share Cash Paid CommonStockDividendsPerShareCashPaid	0
CY2023Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	13309824	shares
CY2022Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	11435241	shares
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11923000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3531000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q1	plrx	Valuation Allowance As Percentage On Deferred Tax Assets ValuationAllowanceAsPercentageOnDeferredTaxAssets	1
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023Q1	plrx	Contractual Arrangements Cancellation Period ContractualArrangementsCancellationPeriod	P30D
CY2018Q1	plrx	Period Of Base Rent Abatement PeriodOfBaseRentAbatement	P2M
CY2018Q1	plrx	Base Rent Abated Amount BaseRentAbatedAmount	200000	usd
CY2022Q3	plrx	Base Rent Abated Amount BaseRentAbatedAmount	100000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	700000	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	700000	usd
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost	200000	usd
CY2022Q1	us-gaap	Variable Lease Cost VariableLeaseCost	100000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	800000	usd
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	600000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	2064000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2422000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1202000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	0	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	0	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	5688000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	458000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2380000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2850000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y1M6D
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y2M12D
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-28100000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-37548000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.082
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.079
CY2023Q1	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	300000	usd
CY2022Q1	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	200000	usd
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7549127	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5203104	shares
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-37548000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-37548000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-28100000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-28100000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	56057603	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36116440	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	56057603	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36116440	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.67
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.78
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.67
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.78

Files In Submission

Name	View Source	Status
plrx-20230331_pre.xml	Edgar Link	unprocessable
0001746473-23-000031-index-headers.html	Edgar Link	pending
0001746473-23-000031-index.html	Edgar Link	pending
0001746473-23-000031.txt	Edgar Link	pending
0001746473-23-000031-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
plrx-20230331.htm	Edgar Link	pending
plrx-20230331.xsd	Edgar Link	pending
plrx-20230331xex311.htm	Edgar Link	pending
plrx-20230331xex312.htm	Edgar Link	pending
plrx-20230331xex321.htm	Edgar Link	pending
plrx-20230331_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
plrx-20230331_def.xml	Edgar Link	unprocessable
plrx-20230331_htm.xml	Edgar Link	completed
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
plrx-20230331_lab.xml	Edgar Link	unprocessable
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PLRX
PLIANT THERAPEUTICS, INC. Stock $plrx

2023 Q2 Form 10-Q Financial Statement

#000174647323000031 Filed on May 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLRX PLIANT THERAPEUTICS, INC. Stock $plrx

2023 Q2 Form 10-Q Financial Statement

#000174647323000031 Filed on May 09, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLRX
PLIANT THERAPEUTICS, INC. Stock $plrx